All Outputs (2)

CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer (2021)
Journal Article
Uzor, S., Porazinski, S., Li, L., Clark, B., Ajiro, M., Iida, K., …Ladomery, M. (2021). CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer. Scientific Reports, 11(1), Article 7963. https://doi.org/10.1038/s41598-021-86908-6

Dysregulation of alternative splicing is a feature of cancer, both in aetiology and progression. It occurs because of mutations in splice sites or sites that regulate splicing, or because of the altered expression and activity of splice factors and o... Read More about CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer.

Epigenenetic regulation of alternative splicing: How lncRNAs tailor the message (2021)
Journal Article
Pisignano, G., & Ladomery, M. (2021). Epigenenetic regulation of alternative splicing: How lncRNAs tailor the message. Non-Coding RNA, 7(1), Article 21. https://doi.org/10.3390/ncrna7010021

Alternative splicing is a highly fine-tuned regulated process and one of the main drivers of proteomic diversity across eukaryotes. The vast majority of human multi-exon genes is alternatively spliced in a cell type-and tissue-specific manner, and de... Read More about Epigenenetic regulation of alternative splicing: How lncRNAs tailor the message.